Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
Healthcare
$3.29 -2.21%
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
52W Low $0.92High $8.69
Volume 0.17M
Average 0.97M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$19.83M
FY 2025 · Annual
Net Income
-$20.85M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.52M | 6.32M | 7.62M | 7.25M | 9.34M |
| Selling, General & Admin | 5.21M | 8.59M | 8.76M | 8.11M | 10.49M |
| Operating Expenses | 7.73M | 14.91M | 16.38M | 15.37M | 19.83M |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| EBITDA | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.73M) | (14.91M) | (16.38M) | (15.37M) | (19.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.72K | 588.11K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17.72K | 588.11K | 955K | 343.72K | (1.02M) |
| Income Before Tax | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| EPS (Diluted) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| 4.09M | 8.26M | 8.4M | 9.36M | 966.12K | |
| 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
INDP Earnings Waterfall · TTM
NASDAQ:INDP · Revenue to Net Income
Key Ratios
EPS$-6.34
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.2
P/S Ratio0.0
Analysis
$0 of revenue converted into -$18.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-6.34, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 22, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 22, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 22, 2026 |
How much revenue does INDP generate?
Indaptus Therapeutics, Inc. (INDP) reported $0.00 of revenue in fiscal 2025.
Is INDP profitable?
Indaptus Therapeutics, Inc. (INDP) reported -$20.85M of net income.
Continue the stock analysis
Jump to another research area for this company.